Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
VANCOUVER, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold” or the “Company”), a clean-technology company enabling the ...
Interim phase 3 trial data show that atacicept reduces proteinuria over 36 weeks in patients with IgA nephropathy. Patients with IgA nephropathy treated with atacicept experience substantial reduction ...
Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now it can celebrate a key trial win for its first drug to gain an FDA approval in ...
Hosted on MSN
Tricky Phase 3 Madness Reaction
VaporTheGamer reacts to tricky mod phase 3 is literal madness! [part 1] with fun commentary, unique insights, and FNAF or FNF fan excitement. VIDEO: Hay fraud hits local farms Flooded outfield results ...
Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...
aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback